verified99%+ Verified Purity
local_shippingFast EU Delivery (through resellers)
Myotrope
Homechevron_rightAll Peptideschevron_rightTirzepatide Injection Pen
Tirzepatide Injection Pen
verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-tirzepatide-injection-pen-10mg

Official Product Data Sheet

Tirzepatide Injection Pen (10mg)

High >98% Purity

Vial Contents
10 mg Tirzepatide (3 mL pre-filled injection pen)
Includes
Ready-to-use multi-dose injection pen — no mixing required
Form
Pre-filled multi-dose pen
Purity
≥98%, third-party verified
Sequence
Dual GIP/GLP-1 Agonist
Molecular Formula
See chemical properties
Molecular Mass
≈4813 g/mol
CAS No.
2023788-19-2
Solubility
Concentration: ≈3.33 mg/mL | Per click: 1 unit ≈ 33.33 mcg (0.033 mg)
Storage
Refrigerate at 2–8 °C. Protect from light. Do not freeze.

Authorized Resellers

Available through our trusted partners

12
verifiedVerified

123peptide.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new
DE
verifiedVerified

Depeptidenwinkel.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new
View all authorized resellersshopping_cart
swipe_rightSwipe to see all tabs

Scientific Background

Tirzepatide is a long-acting dual GIP and GLP-1 receptor agonist that simultaneously engages two separate incretin pathways — quieting appetite signals, enhancing insulin sensitivity, and promoting steady calorie burn. Clinical trials demonstrate average weight reductions of approximately 22.5%, making it a leading compound for metabolic and obesity research.

Intended Research Use

  • Dual incretin (GIP + GLP-1) receptor activation research
  • Appetite suppression and portion control studies
  • Targeted visceral fat reduction
  • Glucose metabolism and insulin sensitivity research
  • Comparative efficacy vs. single-receptor GLP-1 agonists

menu_bookScientific Publications

article

N Engl J Med (2022)

Tirzepatide Once Weekly for the Treatment of Obesity

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/35665733/

article

N Engl J Med (2021)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34170647/

article

Lancet (2023)

Tirzepatide once weekly for obesity in people with type 2 diabetes (SURMOUNT-2)

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37385275/

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Myotrope

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

Tirzepatide combines well with peptides targeting complementary fat loss and appetite pathways.

Lemonbottle 10mg

Lemonbottle 10mg (10mg vial)

arrow_forward

myo-lemonbottle-10mg

Targeted fat-loss synergy — Lemonbottle's lipolytic blend targets localised fat deposits while Tirzepatide drives systemic metabolic improvements.

Cagrilintide 5mg

Cagrilintide 5mg (5mg vial)

arrow_forward

myo-cagrilintide-5mg

Enhanced satiety — Cagrilintide's amylin-pathway satiety complements Tirzepatide's dual incretin action for additive appetite suppression.

AOD-9604 5mg

AOD-9604 5mg (5mg vial)

arrow_forward

myo-hgh-fragment-aod-9604-5mg

Targeted fat breakdown — AOD-9604 acts on stubborn adipose areas while Tirzepatide boosts systemic metabolic efficiency.

schedule

Cycling Note: Typical protocol: 12–52 weeks with gradual titration every 4 weeks. Monitor body weight and metabolic markers regularly.

Also Available

Tirzepatide 10mg
Vial

Tirzepatide

10mg

Tirzepatide 15mg
Vial

Tirzepatide

15mg

Tirzepatide 30mg
Vial

Tirzepatide

30mg

Tirzepatide 60mg
Vial

Tirzepatide

60mg